| Description | Linsidomine hydrochloride (SIN-1 chloride) is considered as a metabolite of moxidomine, with vasodilation, inhibition of platelet aggregation, and antiangina activity. In myocardial ischemia-reperfusion models, Linsidomine hydrochloride to reduce myocardial necrosis and reperfusion induced endothelial dysfunction is associated with the cavernosal mechanism of action involved in nitric oxide release. |
| In vitro | SIN-1 在心肌缺血-再灌注模型中减少心肌坏死和再灌注引起的内皮功能障碍[1][2]。 |
| In vivo | SIN-1 (chloride) 是莫索明的活性代谢产物。它显示出强大的血管舒张效应和抑制血小板聚集的功能。[1]在心肌缺血-再灌注模型中，SIN-1（氯化物）能降低心肌坏死和减轻再灌注引起的内皮功能障碍。[2] |
| Synonyms | SIN-1 chloride |
| molecular weight | 206.63 |
| Molecular formula | C6H11ClN4O2 |
| CAS | 16142-27-1 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 22.5 mg/mL (108.9 mM), Sonication and heating to 60℃ are recommended. H2O: 45.0 mg/mL (217.8 mM), Sonication is recommended. |
| References | 1. Nishikawa M, et al. Inhibition of platelet aggregation and stimulation of guanylate cyclase by an antianginal agent molsidomine and its metabolites. J Pharmacol Exp Ther. 1982;220(1):183-190. 2. Siegfried MR, et al. Cardioprotection and attenuation of endothelial dysfunction by organic nitric oxide donors in myocardial ischemia-reperfusion. J Pharmacol Exp Ther. 1992;260(2):668-675. |